• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Stents

Abbott has positive data for Esprit drug-eluting resorbable scaffold

October 25, 2023 By Sean Whooley

Abbott [WtwhTicker symbol=”ABT”](NYSE: ABT)[/WtwhTicker] today announced data supporting its Esprit BTK everolimus-eluting resorbable scaffold system. The company designed Esprit BTK to treat people with chronic limb-threatening ischemia (CLTI), a severe stage of peripheral artery disease (PAD). Abbott said its LIFE-BTK trial met both of its primary safety and effectiveness endpoints. It demonstrated the reduction of […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Stents Tagged With: abbott

FDA approves Medinol drug-eluting coronary stent

October 24, 2023 By Danielle Kirsh

Medinol-Elunir-Perl

Medinol this week announced it received FDA approval for its Elunir-Perl drug-eluting stent (DES) for the treatment of coronary artery disease. Elunir-Perl is the latest evolution in the company’s Elunir DES product portfolio. It has four radiopaque markers, two at each end of the stent, as well as a hybrid polymer-metal radiopaque catheter tip. The […]

Filed Under: Drug-Device Combinations, Stents Tagged With: medinol

Boston Scientific hit with $42M verdict in drug-eluting stents IP case

February 2, 2023 By Chris Newmarker

Pixabay stock image of a gavel to go with Boston Scientific drug-eluting stents IP verdict story

Boston Scientific (NYSE:BSX) must pay $42 million in unpaid royalties to TissueGen and the University of Texas, a federal jury in Delaware has ruled. The jury verdict yesterday came after the finding that Boston Scientific’s Synergy BP drug-eluting stents infringed on TissueGen and the university’s IP. The patent under question arose out of research that […]

Filed Under: Featured, Legal News, Stents Tagged With: Boston Scientific, TissueGen

FDA approves Medtronic drug-eluting stents for treating bifurcation lesions

September 21, 2022 By Sean Whooley

Medtronic Resolute Onyx drug-eluting stent

Medtronic (NYSE:MDT) announced today that the FDA approved its Onyx drug-eluting stents (DES) for treating certain lesions. Approval covers the treatment of non-left main bifurcation lesions utilizing the provisional bifurcation stenting technique. The technique uses a single stent to treat the bifurcation in percutaneous coronary interventions (PCIs). It applies to the FDA-approved and CE-marked Onyx […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Oncology, Regulatory/Compliance, Stents, Vascular Tagged With: FDA, Medtronic

Medtronic launches Onyx Frontier drug-eluting stent

August 25, 2022 By Danielle Kirsh

Onyx Frontier Medtronic

Medtronic (NYSE:MDT) launched its newest drug-eluting coronary stent, Onyx Frontier. The Fridley, Minnesota-based company designed the Onyx Frontier drug-eluting stent (DES) to build upon its Resolute Onyx DES. It uses the same stent platform as the Resolute Onyx and has an enhanced delivery system to increase acute performance in interventional coronary artery disease procedures. Get […]

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Stents, Vascular Tagged With: Medtronic

Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy

May 18, 2022 By Sean Whooley

Medtronic Resolute Onyx drug-eluting stent

Data presented today at the EuroPCR 2022 event supported the use of the Medtronic (NYSE:MDT) Resolute Onyx drug-eluting stent. University of Padua Medical School Head of Interventional Cardiology Dr. Giuseppe Tarantini presented late-breaking clinical trial results from the investigator-initiated, Medtronic-funded ROLEX (Revascularization Of LEft Main With Resolute onyX) registry. ROLEX, the largest real-world, multicenter prospective […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Stents, Vascular Tagged With: Medtronic

Ariste Medical co-founder sees great potential for drug-coated implants and orthopedics

April 18, 2022 By Jim Hammerand

Orange polypropylene mesh coated with antibiotics

It’s been more than a decade since Lisa Jennings launched not one but two companies in the Great Recession. In 2020, she sold CirQuest Labs to MLM Medical Labs, where Jennings serves as chief scientific officer and managing director of U.S. operations. More recently, her pre-commercial medtech development startup, Ariste Medical, won FDA 510(k) approval for […]

Filed Under: Drug-Device Combinations, Featured, Grafts, Implants, Materials Testing, Orthopedics, Pharmaceuticals, Research & Development, Stents, Uncategorized Tagged With: Ariste Medical, implantable devices

Ivantis to pay $60M in patent litigation settlement with Glaukos

September 15, 2021 By Sean Whooley

Glaukos logo

Glaukos (NYSE:GKOS) announced today that it entered into a settlement with Ivantis to terminate a three-year-old patent infringement lawsuit. San Clemente, California-based Glaukos’ patent infringement lawsuit, initiated on April 14, 2018, in the U.S. District Court for the Central District of California, Southern Division, concerned Ivantis’ Hydrus Microstent for reducing eye pressure in glaucoma patients. […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Implants, Legal News, Optical/Ophthalmic, Stents Tagged With: Glaukos, Ivantis

Glaukos submits supplemental PMA application for iStent Infinite

September 3, 2021 By Sean Whooley

Glaukos logo

Glaukos (NYSE:GKOS) announced today that it submitted a supplemental premarket approval application to the FDA for its iStent Infinite system. San Clemente, California–based Glaukos designed the iStent Infinite trabecular micro-bypass system for use in a standalone procedure to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma uncontrolled by prior surgery or medical therapy. […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Optical/Ophthalmic, Regulatory/Compliance, Stents Tagged With: FDA, Glaukos

Sinomed launches HT Supreme drug-eluting stent in Europe

August 17, 2021 By Sean Whooley

Sinomed

Sinomed has completed the first commercial implantation of its HT Supreme drug-eluting stent in Ireland. Faisal Sharif, professor of translational cardiovascular medicine and innovation at the National University of Ireland Galway, successfully performed the first procedure with HT Supreme, a healing-targeted drug-eluting stent designed to treat patients with narrowing or blockages to their coronary arteries. […]

Filed Under: Business/Financial News, Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Stents, Vascular Tagged With: drug-eluting stent, drug-eluting stents, HT Supreme, Sinomed, vv

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 6
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS